A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma
NCT04993690
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
200
Enrollment
INDUSTRY
Sponsor class
Conditions
B-cell Lymphoma
Interventions
DRUG:
LP-168 tablet
Sponsor
Guangzhou Lupeng Pharmaceutical Company LTD.